![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, September 14, 2020 11:32:14 AM
They usually are to encourage future shareholders.
These "so called" conferences drive shareholders crazy because traders tend to have their way with the share price around the time of the presentation, often to the down side.
"So called" shareholders often get gifts from these "so called" conferences when the traders drive their price down because they can acquire shares at a cheaper level, but seldom can take advantage due to being "all in" and already "pot committed" with their current portfolio, with no more funds to expend.
There are many ways to make, and to lose money with stocks. The mechanisms that you need to utilize to effectively support your position are very dependent upon the focus you have. Quite often, investors engage in counterproductive activities that inadvertently support traders ..... then publicly complain about it due to their naivete'.
Never buy or sell based on my posts.Always consult with a licensed securities professional before you buy or sell any security.My posts are opinions only.Never use them as due diligence.My positions are subject to change without notice.
Recent CAPR News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/14/2024 08:31:21 PM
- Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway • GlobeNewswire Inc. • 06/11/2024 01:25:00 PM
- Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy • GlobeNewswire Inc. • 06/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 09:05:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 09:00:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 01:00:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:05:49 PM
- Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/13/2024 08:05:00 PM
- Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting • GlobeNewswire Inc. • 05/09/2024 01:15:00 PM
- Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences • GlobeNewswire Inc. • 05/08/2024 01:00:00 PM
- Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13 • GlobeNewswire Inc. • 05/06/2024 01:00:00 PM
- Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy • GlobeNewswire Inc. • 04/24/2024 01:00:00 PM
- Capricor Therapeutics to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 03/21/2024 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2024 12:30:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:06:15 PM
- Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29 • GlobeNewswire Inc. • 02/22/2024 01:30:00 PM
- Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization • GlobeNewswire Inc. • 02/20/2024 01:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/16/2024 10:04:29 PM
- Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2 • GlobeNewswire Inc. • 01/24/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 02:00:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:15:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:15:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:15:32 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM